S100 Proteins As an Important Regulator of Macrophage Inflammation

Chang Xia1,2, Zachary Braunstein3, Amelia C. Toomey4, Jixin Zhong2* and Xiaoquan Rao2*

1 College of Health Science and Nursing, Wuhan Polytechnic University, Wuhan, China, 2 Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, United States, 3 Boonshoft School of Medicine, Wright State University, Dayton, OH, United States, 4 Department of Health Sciences, University of Missouri, Columbia, MO, United States

The S100 proteins, a family of calcium-binding cytosolic proteins, have a broad range of intracellular and extracellular functions through regulating calcium balance, cell apoptosis, proliferation, differentiation, energy metabolism, and inflammation. The intracellular functions of S100 proteins involve interaction with intracellular receptors, membrane protein recruitment/transportation, transcriptional regulation and integrating with enzymes or nucleic acids, and DNA repair. The S100 proteins could also be released from the cytoplasm, induced by tissue/cell damage and cellular stress. The extracellular S100 proteins, serving as a danger signal, are crucial in regulating immune homeostasis, post-traumatic injury, and inflammation. Extracellular S100 proteins are also considered biomarkers for some specific diseases. In this review, we will discuss the multi-functional roles of S100 proteins, especially their potential roles associated with cell migration, differentiation, tissue repair, and inflammation.

Keywords: S100 proteins, inflammation, tissue repair, biomarkers, inflammatory disease, macrophages

INTRODUCTION

The S100 proteins, belonging to a calcium-binding cytosolic protein family, are composed of 25 known members (1–4). They have a broad range of intracellular and extracellular functions encompassing regulation cell apoptosis, proliferation, differentiation, migration, energy metabolism, calcium balance, protein phosphorylation, and inflammation (5–8).

Based on their functional roles, s100 proteins are categorized into three main subgroups: S100 proteins that only exert intracellular functions, S100 proteins that have both intracellular and extracellular roles, and S100 proteins that mainly possess extracellular effects (7). The S100 proteins within the first subgroup only exert intracellular functions. For example, S100A1 is predominantly expressed in striated muscle (especially cardiac muscle) (9) and only exert intracellular regulatory effects such as regulating SR Ca^{2+} recycle and enhancing the gain of the calcium-induced calcium release (CICR) cascade (10–12). In addition to intracellular roles, some S100 proteins are released into the extracellular environment and may exert extracellular functions. S100B in this subgroup was known to directly interact with nuclear Dbf2-related protein kinase (NDR kinase) and block the recruitment of its substrates to NDR kinase (13). Furthermore, extracellular S100B could also activate extracellular signal-regulated protein kinase (ERK) and NfκB in chondrocytes by binding to its cell surface receptor, receptor for advanced glycation end products (RAGE) (14). The third subgroup of S100 proteins such as S100A15 mainly exerts extracellular regulatory functions. These
of S100 proteins are considered as potential therapeutic targets for various human disorders, including arthritis, cancer, and Alzheimer’s disease (15, 16).

S100 proteins are involved in multiple intracellular functions which include: interacting with intracellular receptors or molecule subunits (17), membrane protein recruitment and transportation, transcriptional regulation (18, 19), regulating enzymes, nucleic acids, and DNA repair (20, 21) (Figure 1). There are two critical steps for S100 protein activation: Ca²⁺ binding (22) and homoor hetero-dimer formation (23). Each S100 protein forming the dimer participates in ion (Ca²⁺ or Zn²⁺ or Cu²⁺) binding. Ca²⁺ also contributes to the formation of S100 protein oligomers, especially calprotectin (S100A8/A9 tetramer) (22, 24, 25).

When released to the extracellular space, S100 proteins have crucial activities in the regulation of immune homeostasis, post-traumatic injury, and inflammation. S100 proteins trigger inflammation through interacting with receptors RAGE and TLR4 (26). Increasing evidence has demonstrated that calprotectin (S100A8/A9) is an endogenous agonist of TLR4 (26). Binding to TLR4 initiates a signaling cascade and regulates inflammation, cell proliferation, differentiation, and tumor development in an NF-κB-dependent manner (8, 26–28). Apart from TLR4, RAGE has also been suggested to bind S100 proteins such as S100A7, S100A12, S100A8/A9, and S100B (27, 29–31). By interacting with RAGE, S100 proteins activate NF-κB, inducing the production of pro-inflammatory cytokines leading to the migration of neutrophils, monocytes, and macrophages (30, 31). In addition to the NF-κB pathway, MAP kinase-mediated signaling is also induced by S100 proteins such as S100P (32, 33). Interestingly, S100A6 activates RAGE and promotes apoptosis, while S100B inactivates RAGE by interacting with the basic fibroblast growth factor and its receptor (14, 34). Extracellular S100 proteins may regulate the apoptosis, proliferation, differentiation, and migration of a number of cell types including monocytes, macrophages, neutrophils, lymphocytes, myoblast, epithelial cells, endothelial cells, smooth muscle cells, neurons, and fibroblasts. In this review, we aim to summarize the immune regulatory role of S100 proteins and their potential involvement in inflammatory regulation, tissue repair, and tumorigenesis.

**S100 GENES AND MOLECULAR STRUCTURE**

Each S100 family protein is encoded by a separate gene. Most S100 genes are located within the chromosome 1q21 with a few exceptions. For example, S100A11P is located within chromosome 7q22-q3, S100B in located within chromosome 21q22, S100P is located in chromosome 4p16, S100G is located in chromosome Xp22, and S100Z is located with chromosome 5q13 (5). The sequence homology among S100 proteins varies from 22 to 57%, which is mainly due to the variance at the hinge region and C-terminus, the regions associated with their function (35).

S100 proteins are small proteins with a molecular weight of 10–12 kDa. Each S100 protein consists of two EF-hand helix-loop–helix structural motifs, which are arranged in a back-to-back manner and linked with a flexible hinge (23). The activity of the proteins is regulated by metal ions (such as calcium, zinc, and copper), which modulates the folding and oligomerization of the protein (36, 37).

**EXPRESSION PATTERN AND REGULATION**

Epigenetic mechanisms play a key role in the regulation of S100 protein expression. S100A3, S100A10, S10011, and S100P could be detected in various medulloblastoma cell lines treated with DNA de-methylation (38). It is reported that DNA hypomethylation could induce S100A6 overexpression in gastric cancer. Lower levels of CpG methylation in the first intron and second exon regions of the S100A6 gene, accompanied by higher levels of acetylated histone H3 binding to the promoter, have been reported in the gastric cancer tissues (39). Lower methylation in the proximal promoter region of the S100P gene was also found in prostate cancer cell lines (40). The expression of S100 proteins may also be regulated by micro RNAs, although further studies are needed to provide direct evidence. NFAT5, a transcription factor that initiates S100A4 expression (41), is regulated by miR-568 (42).
The expression of S100 proteins is strictly regulated to maintain immune homeostasis (7, 43). S100A8 and S100A9 are predominately expressed in monocytes, neutrophils, and dendritic cells (44, 45). However, they are also expressed in various other types of cells upon activation, such as fibroblasts (46), mature macrophages (47), vascular endothelial cells (48–50), and keratinocytes (51). In neutrophils, 45% of the cytosolic proteins are constituted with S100A8 and S100A9, whereas the proportion is only 1% in monocytes (52). The expression levels in different monocyte subsets also vary. The level of S100A8 mRNA is higher in classical CD14+CD16− human monocytes when compared to non-classical CD14+CD16+ monocytes (47).

Increasing evidence indicates that the expression of most S100 proteins is different between physiological and pathological conditions. The expression of S100A8 and S100A9 could be upregulated by a number of conditions such as oxidative stress, specific cytokines, and growth factors in many types of cells (53). S100A12 is mainly expressed in neutrophils, monocytes, and early macrophages (53, 54), but it can also be detected in endothelial cells, keratinocytes, epithelial cells, and pro-inflammatory macrophages under inflammatory conditions (51, 55–58). In human epidermal keratinocytes, interleukin (IL)-α/β induces a significant increase of S100A9 expression by the p38 MAPK pathway (59). The expression of S100A5 is upregulated in bladder cancers (60). Pro-inflammatory cytokines could increase S100A7 expression in human breast cancer (61).

S100A8/A9 heterodimer enhances the expression of β2 integrin CD11b and the ability of adhesion in phagocytes (72, 77). Moreover, the response of S100A9−/− monocytes to chemotaxis was reduced when compared with wild-type cells. For example, the release of S100A8/A9 has been suggested to facilitate monocyte and neutrophil transmigration (75, 76). The S100A8/ A9 heterodimer enhances the expression of β2 integrin CD11b and the ability of adhesion in phagocytes (72, 77).

S100 PROTEINS IN MACROPHAGES

It is widely accepted that macrophages contribute to immune defense, immune regulation, and tissue repair. Based on their cytokine production and activation conditions, macrophages are categorized into two populations: pro-inflammatory M1 (classically activated macrophage) and anti-inflammatory M2 (alternatively activated macrophage). Calprotectin could induce pro-inflammatory cytokine production in monocytes and macrophages through NF-κB and p38 MAPK pathways (74). An increasing number of findings demonstrate that S100 proteins contribute to the adhesion and migration of leukocytes. For example, the release of S100A8/A9 has been suggested to facilitate monocyte and neutrophil transmigration (75, 76). The S100A8/A9 heterodimer enhances the expression of β2 integrin CD11b and the ability of adhesion in phagocytes (72, 77).

The intimate relationship between macrophages and cancer cells plays a crucial role in tumor growth and metastasis. Tumor-associated macrophages influence tumor growth by modulating local inflammation, inhibiting antitumor immunity, and stimulating angiogenesis (83–85). It is commonly accepted that macrophages contribute to tumor growth and invasion. They are recruited to the site of tumors via chemoattractants such as CCL3-8, vascular endothelial growth factor (VEGF), and macrophage inflammatory protein-1 alpha (MIP-1α) (86). The monocytes or macrophages tend to differentiate into the M2 macrophage phenotype rather than the tumoricidal M1 phenotype, producing pro-tumor cytokines, such as macrophage colony-stimulating factor, IL-10, IL-4, and IL-13 (83, 87, 88). S100A10 was shown to mediate the migration of macrophages to the tumor site. Tumor growth was reduced in S100A10-null mice, compared with wild-type mice, and was accompanied by less macrophages within the tumor. There were many macrophages throughout the tumor in wild-type mice, where macrophages were observed...
only around the absolute tumor tissue border in S100A10-null mice (89). Intraperitoneal injection of wild-type macrophages restored macrophage density within the tumor, but injection of S100A10-deficient macrophages did not. Interestingly, intratumoral injection of macrophages of either genotype could rescue tumor growth, suggesting that S100A10−/− macrophages still have the ability to stimulate tumor growth but lack the ability to invade into the tumor (89). Another study showed that S100A10 deficiency decreased plasmin generation and matrix metalloproteinase 9 activation in macrophages, both of which are associated with macrophage invasion and migration (90).

Downregulation of S100A8 and S100A9 is associated with the differentiation of myeloid cells toward dendritic cells and macrophages (91, 92). S100A8 and S100A9 are co-expressed in fetal myeloid progenitors, with its expression level associated with the development of the myeloid lineage (93). They are highly expressed in monocytes and neutrophils. However, the expressions of S100A8 and S100A9 are lost when monocytes terminally differentiate into tissue macrophages (93). Recent data have shown that S100A8 can be induced by oxidative stress in macrophages in an IL-10-dependent manner (51). Interestingly, S100A8/A9 has also been shown to control the cell cycle (94). S100A9 inhibited myeloid cells differentiation through generation of ROS (92). S100A9 is able to induce the differentiation of monocytes toward the osteoclast type in vitro culture experiments and S100A9 derived from neutrophils and S100A9-induced osteoclast generation were considered as important reasons for bone degradation in infectious osteomyelitis (95). S100A8 and S100A9 have also been shown to mediate the arresting effect of TNF-α in vitro and in vivo. S100A8/A9 contributes to the release of cytokines and chemokines in a RAGE-dependent manner. This process promoted myocardial tissue inflammation and fibrotic scar formation (103, 104). In a mouse model of collagenase-induced arthritis, the expression of S100A8 and S100A9 in synovial was upregulated in wild-type mice. In addition, S100a9−/− mice were protected from collagenase-induced synovitis, cartilage degradation, and osteophyte formation (105, 106). S100A9 antibodies could block the accumulation of fibroblasts and decrease fibrosis in local inflammatory microenvironment (104). In contrast, S100A1 or S100A4, released following MI, has a beneficial effect following heart injury by promoting muscle tissue repair and maintaining contractility (107, 108).

Binding of S100B to RAGE and the subsequent increase of angiogenic factor VEGF have been shown to be essential in the development of macular degeneration (109). In addition, S100B activates the Ras-MEK-ERK1/2-NF-kB pathway in neural cells and leads to the activation of small GTPases, Rac1/Cdc42, and neurite growth (110). In vascular smooth muscle cells, S100B induces the upregulation of ROS and recruits JAK2 and STAT3, which results in the proliferation of vascular smooth muscle cells (111). Similarly, S100B also increased cellular proliferation through activating the Phosphatidylinositol-4,5-bisphosphate 3-kinase-AKT pathway in a RAGE-dependent manner (14). On the other hand, S100B could induce apoptosis by increasing production of ROS and the release of cytochrome-c from mitochondria (110). High levels of S100B are released from injured cardiomyocytes following MI and could promote cell apoptosis through RAGE. Also, S100B released from injured skeletal muscle tissue could stimulate myoblast proliferation but inhibit myoblast differentiation by activating bFGF/FGFR1 signaling (112, 113). However, the regeneration effects of S100B on the injured myoblasts are strongly dependent on cell density, because it triggers RAGE, but not bFGF/FGFR1 signaling, at an early stage of low-density myoblast differentiation (114).

ROLE OF S100 PROTEINS IN TISSUE REPAIR

Damage-associated molecular pattern molecules play a critical role in tissue repair. S100A7, S100A8/A9, S100A12, and S100A15, well-documented DAMPs, have been shown to participate in inflammatory tissue damage and tissue repair. The link between S100A12 and the severity of coronary and carotid atherosclerosis has been evidenced by multiple human studies (97–99). S100A7 is highly expressed in the skin, and the expression is increased in inflamed skin, which has been shown to be induced by pro-inflammatory cytokines (IL-17 and IL-22) and bacterial products such as flagellin (62), that the increase of S100A7 has been associated with multiple inflammatory skin diseases, such as psoriasis and atopic dermatitis (62, 100). Similarly, the expression of S100A15 was amplified in the epidermis of psoriatic lesions and acted as chemoattractants for immune cells (101). S100A8/A9 exerts anti-inflammatory function in healthy state, while oxidative stress-associated pathological conditions activate their pro-inflammatory functions (102). Increased plasma S100A8/A9 levels have been associated with atherogenesis, plaque vulnerability, myocardial infarction (MI), cardiovascular death, and heart failure. In a mouse model of angiotensin-induced cardiac damage, it was shown that S100A8/A9 released by granulocytes upregulated pro-inflammatory gene expression and induced the release of cytokines and chemokines in a RAGE-dependent manner. This process promoted myocardial tissue inflammation and fibrotic scar formation (103, 104). In a mouse model of collagenase-induced arthritis, the expression of S100A8 and S100A9 in synovial was upregulated in wild-type mice. In addition, S100a9−/− mice were protected from collagenase-induced synovitis, cartilage degradation, and osteophyte formation (105, 106). S100A9 antibodies could block the accumulation of fibroblasts and decrease fibrosis in local inflammatory microenvironment (104). In contrast, S100A1 or S100A4, released following MI, has a beneficial effect following heart injury by promoting muscle tissue repair and maintaining contractility (107, 108).

THE ROLE OF S100 PROTEINS IN INFLAMMATORY DISEASES

S100 proteins, particularly calgranulins, play a significant role in mediating innate and acquired immune responses, which contribute to the development of chronic inflammatory diseases. Calgranulins are associated with joint inflammation in patients with rheumatoid arthritis (RA) (115). The level of S100A8/A9 in the serum and synovial fluid was significantly increased in RA (116, 117). Recent findings showed that S100A8/A9 was upregulated in early but not late phase osteoarthritis (OA) (118). S100A8/A9 plasma levels were increased at baseline in human OA participants. Meanwhile, osteophyte size was drastically reduced in S100A9−/− mice-induced OA (106). It has also been confirmed that S100A8/A9 contributes to cartilage degradation.
and development of inflammatory arthritis in an antigen-induced arthritis model (119). Similar to S100A8/A9, human S100A7 and S100A15 were first confirmed as over-expressed in psoriatic plaques (120). Increasing evidence supports an association of S100A7 with several inflammatory skin diseases, including psoriasis and atopic dermatitis (62, 100). Evidence strongly indicates that S100A8/A9 levels are higher in hypercalprotectinemia, an extremely rare inflammatory disorder (121–123). Although the mechanism is still unclear, it is possible that the releasing of extracellular S100A8/A9 is dysregulated, which accounts for the abnormal increase of calprotectin and subsequent hyperactive inflammatory reaction. It is suggested that S100 proteins are involved in interacting with both the immune system and the pathogen. S100A12 plays a key role in fighting infections. For example, it has been shown that S100A12 plays a critical role in anti-parasite responses (124). In addition to directly killing *Mycobacterium tuberculosis* and *Mycobacterium leprae*, S100A12 is also required for TLR2/1L- and IFN-γ-induced antimicrobial activity against *Mycobacterium* (125). Haley et al. also showed that S100A12 can help to repress the biogenesis and activity of *H. pylori* cag type IV secretion system by binding nutrient zinc, which results in suppressed bacterial growth and viability (126).

S100A8, S100A9, and S100A12 are abundantly expressed by neutrophils. Evidence indicates that these three members of S100 proteins are released by neutrophils, inducing MUC5AC production in airway epithelial cells through activating TLR4 and RAGE signaling pathway. This reveals the relationship between chronic neutrophil inflammation and obstructive airway diseases such as severe asthma, COPD, and cystic fibrosis (127). In correlation with their role in the development of chronic inflammation, S100A8/A9 also participates in the hyperglycemia-induced increase of myelopoiesis occurring in a RAGE-dependent manner in diabetic mice (128). Interestingly, the amount of circulating monocytes and neutrophils were decreased when anti-diabetic treatment normalized the glycemic index of Ldlr<sup>−/−</sup> atherosclerotic mice, which might explain the increased severity of atherosclerosis found in patients with diabetes (128). In accordance with these findings, increased serum concentrations of S100A8/A9 were detected in obese individuals (129). Furthermore, the expression of the macrophage marker CD68 was increased in the visceral adipose tissue (130). Some research of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus indicates that vildagliptin could increase the mRNA expression levels of S100A9 and TNF-α in human hepatocytes. In addition, it may induce the release of S100A8/A9 complex from HL-60 cells via TNF-α-independent manner, which might be a contributing factor of vildagliptin-associated liver dysfunction (131).

**S100 Proteins as Biomarkers in Specific Diseases**

Extracellular S100 proteins are involved in the activation of G protein-coupled receptors, heparan sulfate proteoglycans or N-Glycans, and scavenger receptors in autocrine and paracrine manners (132, 133). Since S100A proteins can be detected in body fluids, such as urine, cerebrospinal fluid, serum, sputum, and feces, extracellular S100 proteins are considered as biomarkers associated with certain diseases (134–137).

It has been suggested that S100A12, S100A8/A9, and S100B are linked to specific diseases and conditions such as autoimmune diseases, stroke, and trauma (138). The level of S100A12 in the blood is increased in the patients with diabetes, which is correlated with a higher risk of cardiovascular disease development (139). Bogdanova et al. detected the serum concentration of S100A12 and other acute-phase inflammatory markers in thirty-five patients with periodic disease (PD) (140). The level of S100A12 in PD was significantly higher compared to other familial periodic fevers. S100A12 was more sensitive to assess the subclinical activity of autoinflammatory diseases, when compared to other inflammatory biomarkers such as neutrophil counts, fibrinogen, C-reactive protein (CRP), and erythrocyte sedimentation rate (140). Similarly, the serum concentrations of S100A12, as a novel biomarker, were shown to be upregulated in patients with Familial Mediterranean fever in comparison to controls (141).

The plasma concentrations of S100A9 were significantly higher in patients with implant-associated infectious osteomyelitis when compared to patients with sterile inflammation or healthy individuals. In addition, S100A9 was associated with osteoclast generation and bone degradation. Therefore, it could serve as a novel diagnostic marker to aid in the differential diagnosis (95). Similarly, serum levels of S100A8 and S100A9 were dramatically increased in IL-1Ra<sup>−/−</sup> mice and contributed to bone erosion, cartilage damage, and synovial inflammation. Thus, they can be considered as a systemic or local biomarker to evaluate the extent of inflammation and inflammatory joint destruction in seronegative arthritis (142). It was shown that the expression of S100A8/A9 was high in human atherosclerotic lesions and the blood levels were also increased in the patients with coronary artery diseases (CAD), which implied S100A8/A9 might act as a biomarker for cardiovascular events (143). Recent research has shown similar findings that serum S100A8/A9 levels were elevated in 178 CAD patients with unstable angina pectoris or acute myocardial infarction, and the level of S100A8/A9 was significantly positively linked with CRP (P < 0.01) (144). These clinical data suggest that S100A8/A9 may become a novel biomarker for CAD (139).

In addition, more studies explored the value S100A8/A9 as a predictive biomarker for autoimmune diseases. In RA, S100A8/A9 was suggested as a potential biomarker in predicting clinical response to monitor treatment (145, 146). Some clinical investigations have indicated that S100A8/A9 levels might be a more sensitive predictor for monitoring synovial inflammation in RA patients when compared with other markers such as CRP levels (147).

The study by Shakeri et al. suggested that S100 B protein could be used as a posttraumatic biomarker for predicting brain death in severely injured patients with exclusive head trauma during the first 6 h after trauma, but found no relationship between S100 B levels and death (148). Pelinka et al. confirmed that *in vitro* S100 B concentrations increased significantly in rats with femoral fractures but not head injury (149). Interestingly, adverse results indicated that there was no difference in S100 B concentrations...
between patients with and without head injury (150). S100B has also been considered as a prognostic marker of the acute phase of neurologic damage (151), predicting the outcome of traumatic brain injury and large volume cerebral infarction (152, 153). The level of serum S100B in ischemic stroke implied a worse outcome secondary to the stroke (154, 155). This research demonstrates that S100 B is correlated to trauma and a worse long-term outcome. S100B has recently been confirmed to be associated with some genetic disorders and was found to be over-expressed in patients with Down syndrome (156, 157). There was also study showing that S100B may be one of the best biomarkers of melanoma (158).

**S100 PROTEINS AS THERAPEUTIC TARGETS IN DISEASE**

Although direct clinical evidence is limited, increasing studies indicate that S100 proteins may also serve as a therapeutic target for certain disease conditions. As mentioned above, S100 proteins are involved in a number of diseases including inflammatory disease. It has been reported that multiple anti-allergic drugs such as amlexanox, cromolyn, and tranilast are able to bind S100A12 and S100A13, and block downstream RAGE signaling (159). Therefore, these drugs may serve as a therapeutic approach to target S100 proteins. Multiple S100 proteins such as S100A4 (160) and S100B (161) have been shown to participate in the neoplastic disorders by binding to P53 and suppressing its phosphorylation (162). Therefore, efforts are being made to restore P53 function by targeting S100 proteins (163). In an in vitro study, Most et al. demonstrated that extracellular S100A1 is endocytosed by the neonatal ventricular cardiomyocytes protects cardiomyocytes from 2-deoxyglucose and oxidative stress-induced apoptosis via activation of ERK (164). Adeno-associated virus-mediated S100A1 gene transfer in failing cardiomyocytes was also shown to be able to restore the contractile function, suggesting a potential implication of AAV-mediated S100A1 gene therapy in heart failure (165, 166). Despite the promising potentials, the feasibility and safety of these approaches and issues such as how to control and keep expression levels in the therapeutic window need to be further investigated (166).

**CONCLUSION**

Evidence strongly supports that S100 proteins, as a remarkable multifunctional proteins family, are involved in the regulation of several important biological processes such as the inflammatory response, protecting the intra- and extracellular environments during infection, cell proliferation and differentiation, tumor growth and metastasis, cell apoptosis, energy, and glutathione metabolism. However, the activities of all members S100 proteins depend on the cell-specific expression patterns and binding targets even the local microenvironment. Extracellular effects of S100 proteins interact with receptors including TLR-4, RAGE, and heparan sulfate proteoglycans during infection and inflammation which associated with the pathogenesis of inflammatory such as autoimmune disease, infectious diseases, allergy, tumorigenesis and metastasis, and anti-microbial disease. Extracellular S100 proteins can also contribute to the regulation of tissue development and regeneration or repair, which is essential for elucidating their role in the pathological procession of tissue damage, cell apoptosis, or tissue repair.

Although growing evidence has begun to show the regulation of S100 proteins in detail which improves our understanding of how immune homeostasis is maintained during the development of S100 protein-associated disease, there are certain gaps in our understanding of the role of S100 proteins in pathophysiology. Among 25 known members of S100 family, only limited number of S100 proteins such as S100A8 and S100A9 have been well documented and the functional roles of other members are underappreciated. In addition, further studies are required to fully reveal the underlying mechanisms by which S100 proteins participate in a variety of disease conditions. For instance, a role of S100P has been reported in leukemia (167), while the exact function of S100P in leukemia and the signal pathways involved in this process are not completely understood. Also, the direct clinical evidence of the therapeutic potential of S100 proteins is limited at current stage. Therefore, future directions in this area could focus on the development of therapeutic approaches targeting S100 proteins, verification of the therapeutic potential of S100 proteins in both preclinical and clinical settings, and elucidation of the underlying mechanisms.

**AUTHOR CONTRIBUTIONS**

CX and JZ reviewed the literature and wrote the first draft. ZB, AT, JZ, and XR reviewed the literature and finalized the manuscript.

**FUNDING**

This work was supported by grants from National Natural and Scientific Foundation of China (81670431 and 81101247), NIH (K99ES026241 and K01DK105108), AHA (17GRNT33670485), and Natural Science Foundation of Zhejiang Province (No. Y2110580). These funding supports did not lead to any conflict of interests regarding the publication of this manuscript.

**REFERENCES**

1. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun (1965) 19:739–44. doi:10.1016/0006-291X(65)90320-7
2. Moore BW, McGregor D. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem (1965) 240:1647–53.
3. Moore BW, Perez VI, Gehring M. Assay and regional distribution of a soluble protein characteristic of the nervous system. J Neurochem (1968) 15:265–72. doi:10.1111/j.1471-4159.1968.tb1610.x
4. Potts BC, Smith J, Akke M, Macke TJ, Okazaki K, Hidaka H, et al. The structure of calcylcin reveals a novel homodimeric fold for S100 Ca(2+)-binding proteins. Nat Struct Biol (1995) 2:790–6. doi:10.1038/nsb0995-790
22. Brophy MB, Hayden JA, Nolan EM. Calcium ion gradients modulate the
24. Korndorfer IP, Brueckner F, Skerra A. The crystal structure of the human
23. Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM. Natural and amyloid
20. Berge G, Maelandsmo GM. Evaluation of potential interactions between the
17. Donato R. S100: a multigenic family of calcium-modulated proteins of
10. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M, et al.
12. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, et al. Distinct
9. Zimmer DB, Landar A. Analysis of S100A1 expression during skeletal
118:421–31. doi:10.1242/jcs.01614
13. Bhattacharya S, Large E, Heizmann CW, Hemmings B, Chazin WJ. Structure of the Ca(2+)/S100N/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. Biochemistry (2003) 42:14416–26. doi:10.1021/bi033089a
17. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol (2002) 7:d1356–68. doi:10.2741/A846
16. Zheng Y, Zhou Y, Zhao X, Jiang H, Wu J, Xie Y et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol (2008) 83:1484–92. doi:10.1189/jlb.0607397
15. Marshak DR, Pena LA. Potential role of S100 beta in Alzheimer’s disease: an hypothesis involving mitotic protein kinases. Prog Clin Biol Res (1992) 379:289–307.
14. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol (2006) 1:1054–65. doi:10.2215/CJN.02233105
13. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol (2001) 33:637–68. doi:10.1016/S1357-2725(01)00462-2
12. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, et al. Distinct subcellular localization of the Ca2+-binding protein S100A11 differentially modulates Ca2+ cycling in ventricular rat cardiomyocytes. J Cell Sci (2005) 118:421–31. doi:10.1242/jcs.01614
11. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M, et al. Calcium ion gradients modulate the
10. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M, et al. Calcium ion gradients modulate the
S100 Proteins in Macrophage Inflammation

45. Avellini MM, Barnhart S, Becker L, Li X, Heinjeck JW, Lebouef RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerotic and adipose tissue inflammation. Circulation (2011) 123:1216–26. doi:10.1161/CIRCULATIONAHA.110.985523

46. Rahimi F, Hsu K, Endoh Y, Geczy CL. FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS (2005) 272:2811–27. doi:10.1111/j.1742-4658.2005.04703.x

47. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood (2010) 115:2910–9. doi:10.1182/blood-2009-07-235028

48. Ven T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshita T, et al. Induction of the 100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood (1997) 90:1812–21.

49. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem (2005) 280:41521–9. doi:10.1074/jbc.M509442200

50. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. J Cell Biochem (2008) 104:453–64. doi:10.1002/jcb.21024

51. Grimbaldeston MA, Geczy CL, Tedla N, Finlay-Jones JJ, Hart PH. S100A8 regulates fibroblast expression of S100A8. J Cell Biochem (1995) 60:29–39. doi:10.1002/jcb.2880600078

52. Stoll SW, Zhao X, Elder JT. EGF stimulates transcription of CaN19 (S100A2) and RAGE ligands. J Cell Physiol (2012) 227:2214–23. doi:10.1002/jcp.23243

53. Ravasi T, Hsu K, Goyette J, Schroder K, Yang Z, Rahimi F, et al. Probing RAGE-mediated calcium influx in murine microvascular endothelial cells by ultraviolet A irradiation. J Invest Dermatol (2003) 121:1168–74. doi:10.1046/j.1523-1747.2003.12561.x

54. Geczy CL, Tedla N, Finlay-Jones JJ, Hart PH. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem (2011) 286:70227–37. doi:10.1074/jbc.M111.282089

55. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, et al. S100A7 (psoriasin) protects human skin from infection by Escherichia coli. Nat Immunol (2005) 6:57–64. doi:10.1038/nri1412

56. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogt T, Feldmann M, et al. Alarmins: awaiting a clinical response. J Clin Invest (2012) 122:2711–9. doi:10.1172/JCI62423

57. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect Biol (2012) 4:a006049. doi:10.1101/cshperspect.a006049

58. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. J Cell Biochem (2008) 104:247–57. doi:10.1002/jcb.21639

59. Bando M, Zou X, Hiroshima Y, Kataoka M, RossKF, Shinohara Y, et al. Mechanism of interleukin-1alpha transcriptional regulation of S100A9 in a human epidermal keratinocyte cell line. Biochim Biophys Acta (2013) 1829:934–62. doi:10.1016/j.bbabio.2013.03.010

60. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res (2007) 27:3051–8.

61. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res (2012) 72:604–15. doi:10.1158/0008-5472.CAN-11-0669

62. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM. Antimicrobial porriosis (S100A7) protects human skin from Escherichia coli infection. Nat Immunol (2005) 6:57–64. doi:10.1038/nri1412

63. Kim JH, Oh SH, Kim EL, Park SJ, Hong SP, Cheon JH, et al. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myoid cells in the colorectal cancer microenvironment. Biochem Biophys Res Commun (2012) 423:60–6. doi:10.1016/j.bbrc.2012.05.081

64. Dapunt U, Gaida MM, Meyele E, Prior B, Hensch GM. Activation of phagocytic cells by Staphylococcus epidermidis biofilms: effects of extracellular matrix proteins and the bacterial stress protein GroEL on netosis and MRP-14 release. Pathog Dis (2016) 74:24. doi:10.1093/infdis/jiw035

65. Kligman D, Hilton DC. The S100 protein family. Trends Biochem Sci (1988) 13:437–43. doi:10.1016/0968-0004(88)90218-6

66. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124:263–6. doi:10.1016/j.cell.2006.01.007

Frontiers in Immunology | www.frontiersin.org 8 January 2018 | Volume 8 | Article 1908

Xia et al.
85. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. *J Clin Invest* (2007) 117:1155–66. doi:10.1172/JCI17927

86. Dandekar RC, Kingsaonkar AV, Dhabekar GS. Role of macrophages in malignancy. *Ann Maxillofac Surg* (2011) 1:150–4. doi:10.4103/2213-0746.92782

87. Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. *Eur J Cancer* (2006) 42:717–27. doi:10.1016/j.ejca.2006.01.003

88. Lewis CE, Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiogenesis. 2. *Breast Cancer Res* (2007) 9:209. doi:10.1186/bcr1679

89. Dapunt U, Giese T, Maurer S, Stegmaier S, Prior B, Hansch GM, et al. Macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. *Eur J Cancer* (2006) 42:717–27. doi:10.1016/j.ejca.2006.01.003

90. O’Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. *Blood* (2010) 116:1136–46. doi:10.1182/blood-2010-01-264754

91. Cheng P, Corso CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. S100 protein subcellular localization during epidermal differentiation and psoriasis. *J Exp Med* (2008) 205:2235–49. doi:10.1084/jem.20080132

92. Legasse E, Weissman IL. Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage. *Blood* (1992) 79:1907–15.

93. Khamamivong A, Wang C, Sorenson BS, Ross KF, Herzberg MC. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. *PLoS One* (2013) 8:e69335. doi:10.1371/journal.pone.0069395

94. Rapaport EF, Giese T, Maurer S, Stegmaier S, Prior B, Hansch GM, et al. Neutrophil-derived MRP-14 is up-regulated in infected osteomyelitis and stimulates osteoclast generation. *J Leuk Biol* (2015) 98:575–82. doi:10.1189/jlb.13VMA1014-482R

95. Sade-Feldman M, Kanantaier J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. *Immunity* (2013) 38:541–54. doi:10.1016/j.immuni.2013.02.007

96. Goyette J, Yan WX, Y an E, Chung YM, Lim SY, Hsu K, et al. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. *J Immunol* (2009) 183:593–603. doi:10.4049/jimmunol.0800373

97. Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N, Matsushima K. Tumour-associated macrophages are systemic mediators of inflammation in psoriasis. *J Dermatol* (2006) 33:620–5. doi:10.1111/j.1600-0619.2005.02208.x

98. Perera C, Mcneil HP, Geczy CL. S100 calgranulins in inflammatory arthritis. *Ann Rheum Dis* (2006) 65:621–7. doi:10.1136/ard.2007.077800

99. Zreiqat H, Belluoccio D, Smith MM, Wilson R, Rowley LA, Jones K, et al. S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. *J Invest Med* (2013) 61:861–6. doi:10.2310/JIM.0b013e31829229b1e

100. Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. *J Histoch Fucm* (2003) 51:675–85. doi:10.1021/jf020505i

101. Patrakr N, Atuler N, Djalibarier D, Zack Howard OM, Zreiqat H, Belluoccio D, et al. Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family. *FASEB J* (2003) 17:1969–71. doi:10.1096/fj.03-0148fe
121. Fessatuos S, Fagerhol MK, Roth J, Stamoulakatou A, Kitra V, Hadarean M, et al. Severe anemia and neutropenia associated with hyperzinemia and hypercalprotectinemia. *J Pediatr Hematol Oncol* (2005) 27:477–80. doi:10.1097/01.mph.0000179958.19524.9c

122. Isidor B, Poignant S, Corradini N, Fouassier M, Quartier P, Roth J, et al. Hyperzinemia and hypercalprotectinemia: unsuccessful treatment with tacrolimus. *Acta Paediatr* (2009) 98:410–2. doi:10.1111/j.1651-2227.2008.01092.x

123. Vaos G, Kostakis ID, Zavras N, Chatzemichael A. The role of calprotectin in pediatric disease. *Biomed Res Int* (2013) 2013:542363. doi:10.1155/2013/542363

124. MoرزOV, Antson AA, Grist SJ, Mortensen OH, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Andersen S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al. A heterocomplex formed by the calcium-binding proteins MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. *Ann Rheum Dis* (2011) 70:2075–81. doi:10.1136/ard.2011.152496

125. Bolzonella S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with malignant melanoma. *Int J Cancer* (2005) 115:2370–6. doi:10.1002/ijc.23794

126. Haley KP, Delgado AG, Piazuelo MB, Mortensen BL, Correa P, Damo SM, et al. Realegeno S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al. A heterocomplex formed by the calcium-binding proteins MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. *Ann Rheum Dis* (2011) 70:2075–81. doi:10.1136/ard.2011.152496

127. Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calgranulin C is a highly sensitive autoinflammation activity indicator in patients with familial periodic fevers. *Ter Arkh* (2016) 88:58–64. doi:10.17116/terarkh201688658-64

128. Kallinich T, Wittkowski H, Kozierer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. *Ann Rheum Dis* (2016) 75:667–72. doi:10.1136/ard.2014.113463

129. Moroz OV, Antson AA, Grist SJ, Mortensen OH, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Andersen S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al. A heterocomplex formed by the calcium-binding proteins MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. *Ann Rheum Dis* (2011) 70:2075–81. doi:10.1136/ard.2011.152496

130. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Rotellar F, Valenti V, et al. Increased levels of calprotectin in obesity are related to macrophage inflammation and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human macrophages. *PLoS Pathog* (2016) 12:e1005705. doi:10.1371/journal.ppat.1005705

131. Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, Fujiwara R. Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human macrophages. *PLoS Pathog* (2016) 12:e1005705. doi:10.1371/journal.ppat.1005705

132. van den Bos C, Roth J, Stamoulakatou A, Kitra V, Hadarean M, et al. Severe anemia and neutropenia associated with hyperzinemia and hypercalprotectinemia. *J Pediatr Hematol Oncol* (2005) 27:477–80. doi:10.1097/01.mph.0000179958.19524.9c

133. Isidor B, Poignant S, Corradini N, Fouassier M, Quartier P, Roth J, et al. Hyperzinemia and hypercalprotectinemia: unsuccessful treatment with tacrolimus. *Acta Paediatr* (2009) 98:410–2. doi:10.1111/j.1651-2227.2008.01092.x

134. Yang Z, Tao T, Raftery MJ, Youssif P, Di Girolamo N, Geczy CL. Gazzolo D, Michetti F. Perinatal S100B protein assessment in human uncon-
158. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, et al. Biomarkers in melanoma. *Ann Oncol* (2009) 20(Suppl 6):vi8–13. doi:10.1093/annonc/mdp251

159. Shishibori T, Oyama Y, Matsushita O, Yamashita K, Furuichi H, Okabe A, et al. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. *Biochem J* (1999) 338(Pt 3):583–9. doi:10.1042/bj3380583

160. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. *J Biol Chem* (2005) 280:20833–41. doi:10.1074/jbc.M412653200

161. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, et al. A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. *Cancer Invest* (2007) 25:285–93. doi:10.1080/073579006701208634

162. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. *Proc Natl Acad Sci U S A* (2005) 102:4735–40. doi:10.1073/pnas.0501459102

163. Gieldon A, Mori M, Del Conte R. Theoretical study on binding of S100B protein. *J Mol Model* (2007) 13:1123–31. doi:10.1007/s00894-007-0231-6

164. Most P, Boerries M, Eicher C, Schweda C, Ehlermann P, Pleger ST, et al. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). *J Biol Chem* (2003) 278:48404–12. doi:10.1074/jbc.M308587200

165. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. *Sci Transl Med* (2011) 3:92ra64. doi:10.1126/scitranslmed.3002097

166. Ritterhoff J, Most P. Targeting S100A1 in heart failure. *Gene Ther* (2012) 19:613–21. doi:10.1038/gt.2012.8

167. Tsumura H, Akimoto M, Kiyota H, Ishii Y, Ishikura H, Honma Y. Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture. *Leukemia* (2009) 23:753–60. doi:10.1038/leu.2008.347

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Xia, Braunstein, Toomey, Zhong and Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.